Abstract
Since it is the largest cause of death globally, cardiovascular disease (CVD) poses a serious health issue. Whether or whether they are changeable, several risk factors exist for the onset of CVD. Conventional and most often used approach to estimate cardiovascular risk is Framingham risk score. Still, ongoing research is looking for alternative markers that can better estimate this risk. One of these producers under increasing research attention is fibroblast growth factor 23 (FGF-23). The aim of this work is to investigate in patients with type 2 diabetes mellitus a possible prognostic value of plasma and urine FGF-23 for CVD. Two groups—the patients' group and the control group—will be formed out of the 200 participants split equally. The group of patients will include those with type 2 diabetes mellitus of more than five years. Using the Framingham risk score, all participants will be evaluated for their 10-year CVD risk; the outcomes will be statistically linked to both plasma and urine FGF-23. Our present work revealed a positive association between Framingham risk and cholesterol, TG, LDL, HDL, VLDL, non-VLDL. and also showed favorable link in Atherogentic index and BMI,HDL,LDL,VLDL and non LDL. In Dm.patient group and farmingham risk, the FGF23 in current study show greater signifcant.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call